NASDAQ:PRTG

Portage Biotech (PRTG) Stock Forecast, Price & News

$2.55

-0.06 (-2.30%)

(As of 09/21/2023 ET)

Compare

Today's Range: $2.49
▼
$2.59
50-Day Range: $2.35
▼
$3.45
52-Week Range: $2.30
▼
$8.03

Volume: 11,017 shs
Average Volume: 23,712 shs
Market Capitalization: $45.39 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.67

Portage Biotech MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 396.7% Upside
$12.67 Price Target
Short Interest: Healthy
0.09% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

221st out of 965 stocks

Crude Petroleum & Natural Gas Industry

45th out of 78 stocks

3.5

Analyst's Opinion

Consensus Rating
Portage Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.67, Portage Biotech has a forecasted upside of 396.7% from its current price of $2.55.
Amount of Analyst Coverage
Portage Biotech has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.09% of the float of Portage Biotech has been sold short.
Short Interest Ratio / Days to Cover
Portage Biotech has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Portage Biotech has recently decreased by 27.37%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Portage Biotech does not currently pay a dividend.
Dividend Growth
Portage Biotech does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PRTG.

3.2

News and Social Media Coverage

News Sentiment
Portage Biotech has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Portage Biotech this week, compared to 0 articles on an average week.
MarketBeat Follows
2 people have added Portage Biotech to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Portage Biotech insiders have not sold or bought any company stock.
Percentage Held by Insiders
42.07% of the stock of Portage Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 2.00% of the stock of Portage Biotech is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Portage Biotech is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Portage Biotech is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Portage Biotech has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Portage Biotech (NASDAQ:PRTG) Stock

Portage Biotech Inc., together with its subsidiaries, research and develops pharmaceutical and biotechnology products. The company's product pipeline includes IMM60, an iNKT cell activator that is in phase I clinical trial; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; TT-4, an adenosine receptor type 2B (A2B) inhibitor to treat solid tumors; TT-53, an A2A/A2B inhibitor to treat solid tumors; TT-10, an adenosine receptor type 2A (A2A) inhibitor to treat A2A expressing solid tumors; TT-3, an A2B inhibitor to treat colorectal and gastrointestinal cancers; and INT230-6 for the treatment of tumors. It also provides Nanolipogel co-formulation platform for delivery of DNA aptamers and certain aptamer-small molecule-based combination products; and STING agonist platform, a proprietary immune priming and boosting technology, offers various ways to target immune stimulation towards the cancer, as well as to co-deliver various signals in a single product. The company is based in Tortola, British Virgin Islands.

PRTG Price History

30 days | 90 days | 365 days | Advanced Chart

PRTG Stock News Headlines

September 20, 2023 | finance.yahoo.com

Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference

September 7, 2023 | markets.businessinsider.com

Analyst Expectations for Portage Biotech's Future

September 22, 2023 | The Oxford Club (Ad)

Better Than Oil Stocks?

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

September 5, 2023 | marketwatch.com

Portage Biotech in Keytruda Collaboration With Merck

September 5, 2023 | finance.yahoo.com

Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors

September 1, 2023 | msn.com

Cantor Fitzgerald Reiterates Portage Biotech (PRTG) Overweight Recommendation

August 30, 2023 | finance.yahoo.com

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update

August 2, 2023 | msn.com

HC Wainwright & Co. Maintains Portage Biotech (PRTG) Buy Recommendation

September 22, 2023 | The Oxford Club (Ad)

Better Than Oil Stocks?

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

August 2, 2023 | markets.businessinsider.com

Portage Biotech Inc (PRTG) Receives a Buy from H.C. Wainwright

August 2, 2023 | health.usnews.com

University Hospitals Portage Medical Center

August 1, 2023 | msn.com

Cantor Fitzgerald Maintains Portage Biotech (PRTG) Overweight Recommendation

July 31, 2023 | finance.yahoo.com

Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update

June 26, 2023 | finance.yahoo.com

Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors

June 5, 2023 | benzinga.com

Why Portage Biotech Stock Is Up Today

June 5, 2023 | finance.yahoo.com

Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting

June 1, 2023 | finance.yahoo.com

Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference

April 29, 2023 | usnews.com

Portage Central High School

April 26, 2023 | finance.yahoo.com

Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

April 19, 2023 | usnews.com

Portage High School

April 12, 2023 | nytimes.com

Track Covid-19 in Portage County, Wisconsin

March 12, 2023 | benzinga.com

Portage Biotech Stock (NASDAQ:PRTG), Dividends

March 7, 2023 | finance.yahoo.com

Portage Biotech to Present at Oppenheimer’s 33rd Annual Healthcare Conference

March 1, 2023 | finance.yahoo.com

Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022

February 27, 2023 | finance.yahoo.com

Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer

February 23, 2023 | msn.com

Portage Biotech reports FY results

February 15, 2023 | finance.yahoo.com

Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit

See More Headlines

Receive PRTG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Portage Biotech and its competitors with MarketBeat's FREE daily newsletter.

PRTG Company Calendar

Last Earnings: 8/30/2023
Today: 9/22/2023
Next Earnings (Estimated): 12/05/2023
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Crude petroleum & natural gas
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PRTG
CUSIP: N/A
CIK: 1095435
Web: www.portagebiotech.com
Phone: 416-929-1806
Fax: N/A
Employees: 7
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $12.67
High Stock Price Forecast: $18.00
Low Stock Price Forecast: $9.00
Forecasted Upside/Downside: +396.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($6.67)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-104,610,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -88.07%
Return on Assets: -69.67%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.13
Quick Ratio: 4.13

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.45 per share
Price / Book: 0.57

Miscellaneous

Outstanding Shares: 17,800,000
Free Float: 10,312,000
Market Cap: $45.39 million
Optionable: Not Optionable
Beta: 1.31

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. Ian B. Walters M.B.A. (Age 55)
M.D., CEO & Chairman of Board
Comp: $967.65k

Mr. Allan J. Lee Shaw CPA (Age 59)
Chief Financial Officer
Comp: $524.08k

Mr. Steven Innaimo
VP of Project Management & Operations

Dr. Robert A. Kramer Ph.D.
Chief Scientific Officer

Mr. Brian Wiley (Age 55)
Chief Bus. Officer
Comp: $220.69k

Mr. Justin Fairchild
VP of Devel.

Mr. Joseph Ciavarella
Chief Accounting Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

PRTG Stock - Frequently Asked Questions

Should I buy or sell Portage Biotech stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Portage Biotech in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRTG shares.
View PRTG analyst ratings or view top-rated stocks.
What is Portage Biotech's stock price forecast for 2023?: 3 Wall Street research analysts have issued 1 year price targets for Portage Biotech's stock. Their PRTG share price forecasts range from $9.00 to $18.00. On average, they predict the company's share price to reach $12.67 in the next year. This suggests a possible upside of 396.7% from the stock's current price.
View analysts price targets for PRTG or view top-rated stocks among Wall Street analysts.
How have PRTG shares performed in 2023?: Portage Biotech's stock was trading at $5.2891 at the start of the year. Since then, PRTG stock has decreased by 51.8% and is now trading at $2.55.
View the best growth stocks for 2023 here.
Are investors shorting Portage Biotech?: Portage Biotech saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 6,900 shares, a decline of 27.4% from the August 15th total of 9,500 shares. Based on an average trading volume of 12,700 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.1% of the company's stock are sold short.
View Portage Biotech's Short Interest.
When is Portage Biotech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, December 5th 2023.
View our PRTG earnings forecast.
How were Portage Biotech's earnings last quarter?: Portage Biotech Inc. (NASDAQ:PRTG) announced its earnings results on Wednesday, August, 30th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.09.

What is Portage Biotech's stock symbol?: Portage Biotech trades on the NASDAQ under the ticker symbol "PRTG."
Who are Portage Biotech's major shareholders?: Portage Biotech's stock is owned by many different retail and institutional investors. Top institutional investors include Bison Wealth LLC (1.20%), Citadel Advisors LLC (0.11%), Ieq Capital LLC (0.09%), Renaissance Technologies LLC (0.06%) and Simplex Trading LLC (0.00%).
How do I buy shares of Portage Biotech?: Shares of PRTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Portage Biotech's stock price today?: One share of PRTG stock can currently be purchased for approximately $2.55.
How much money does Portage Biotech make?: Portage Biotech (NASDAQ:PRTG) has a market capitalization of $45.39 million. The company earns $-104,610,000.00 in net income (profit) each year or ($6.67) on an earnings per share basis.
How can I contact Portage Biotech?: Portage Biotech's mailing address is Craigmuir Chambers Road Town, Tortola D8, VG1110. The official website for the company is www.portagebiotech.com. The company can be reached via phone at 416-929-1806.

This page (NASDAQ:PRTG) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial